Valuation: Grace Therapeutics, Inc.

Market Cap 47.7M 34.04M 29.57M 27.46M 25.32M 3.25B 48.56M 325M 127M 1.61B 128M 125M 5.43B P/E 2027 *
-3.98x
P/E 2028 * -3.78x
Enterprise Value 47.7M 34.04M 29.57M 27.46M 25.32M 3.25B 48.56M 325M 127M 1.61B 128M 125M 5.43B EV / Sales 2027 *
-
EV / Sales 2028 * 6.09x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day-1.44%
1 week-12.77%
Current month-9.69%
1 month-9.69%
3 months-8.48%
6 months-43.53%
Current year-40.75%
1 week 1.85
Extreme 1.85
2.44
1 month 1.85
Extreme 1.85
2.58
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.07
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 03/04/2023
Director of Finance/CFO 55 04/01/2024
Chief Tech/Sci/R&D Officer 65 07/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 03/04/2023
Director/Board Member 59 09/10/2023
Date Insider Type Main position Quantity % Market Cap.
12/01/26 Option

Chairman

10,000 0.0646%
12/01/26 Option

Director

10,000 0.0646%
12/01/26 Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-12.77%-30.98%-20.54% 33.85M
-3.74%-6.32%+42.70%+63.37% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.73%+0.21%-16.17%-15.27% 23.51B
-2.43%-6.27%-4.28%+355.77% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
+0.03%-0.51%+50.22%+180.90% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -2.28%-2.62%+28.10%+138.65% 23.76B
Weighted average by Cap. -2.30%-0.46%+30.39%+121.32%

Financials

2027 *2028 *
Net sales - 7.83M 5.59M 4.86M 4.51M 4.16M 534M 7.98M 53.38M 20.9M 265M 20.99M 20.53M 891M
Net income -12.76M -9.11M -7.91M -7.34M -6.77M -869M -12.99M -86.95M -34.05M -432M -34.19M -33.45M -1.45B -20.46M -14.6M -12.69M -11.78M -10.86M -1.39B -20.83M -139M -54.6M -692M -54.84M -53.64M -2.33B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
30/07/26 US$2.050 -1.44% 156,012
29/07/26 US$2.080 -7.56% 1,356,856
28/07/26 US$2.250 -2.17% 517,937
27/07/26 US$2.300 -1.29% 116,860
24/07/26 US$2.330 -0.85% 127,089
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.931CAD
Average target price
8.472CAD
Spread / Average Target
+189.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock